Printer Friendly

China International Exchange and Promotive Association grants notification of the acceptance to Nutra Pharma's Nyloxin.

M2 EQUITYBITES-May 4, 2015-China International Exchange and Promotive Association grants notification of the acceptance to Nutra Pharma's Nyloxin

(C)2015 M2 COMMUNICATIONS http://www.m2.com

The China International Exchange and Promotive Association for Medical and Healthcare has granted notification of the acceptance to Nutra Pharma, a biotechnology company that is developing treatments for Multiple Sclerosis, Human Immunodeficiency Virus, Adrenomyeloneuropathy and Pain, for its Nyloxin, it was reported on Friday.

This process was conducted by the Vancouver Commodities Group, which had been chosen by Nutra Pharma to start the process of identifying and selecting potential distributors in China for the Company's Over-the-Counter pain drug, Nyloxin.

Nutra Pharma chairman and CEO, Rik Deitsch, said, 'We only released the engagement of VCG last week and we've already seen some results from their efforts. We've received notification from the vice-chairman of CPAM, stating a positive review of Nyloxin and their willingness to aid us in the registration and distribution of our products throughout China.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Geographic Code:9CHIN
Date:May 4, 2015
Words:172
Previous Article:Dustin Norway extends agreement with Tradebroker for three years.
Next Article:Theraclone collaborates with BIO Ventures for Global Health.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters